Daniel Abdun-Nabi Sells 1,319 Shares of Emergent Biosolutions Inc (NYSE:EBS) Stock

Share on StockTwits

Emergent Biosolutions Inc (NYSE:EBS) CEO Daniel Abdun-Nabi sold 1,319 shares of Emergent Biosolutions stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $65.00, for a total value of $85,735.00. Following the completion of the transaction, the chief executive officer now directly owns 194,787 shares in the company, valued at $12,661,155. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Daniel Abdun-Nabi also recently made the following trade(s):

  • On Friday, September 14th, Daniel Abdun-Nabi sold 28,220 shares of Emergent Biosolutions stock. The stock was sold at an average price of $65.00, for a total value of $1,834,300.00.
  • On Wednesday, September 5th, Daniel Abdun-Nabi sold 90,776 shares of Emergent Biosolutions stock. The stock was sold at an average price of $60.18, for a total value of $5,462,899.68.

Shares of EBS stock traded up $0.83 during trading hours on Friday, reaching $60.80. The company’s stock had a trading volume of 279,905 shares, compared to its average volume of 343,086. The firm has a market cap of $3.29 billion, a P/E ratio of 32.00, a P/E/G ratio of 1.40 and a beta of 1.23. Emergent Biosolutions Inc has a one year low of $36.38 and a one year high of $67.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.15 and a current ratio of 5.59.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.19. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The company had revenue of $220.20 million for the quarter, compared to analyst estimates of $208.94 million. During the same period in the previous year, the company posted $0.13 earnings per share. The firm’s revenue was up 118.5% on a year-over-year basis. As a group, equities analysts predict that Emergent Biosolutions Inc will post 2.35 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stratos Wealth Partners LTD. bought a new stake in shares of Emergent Biosolutions during the first quarter valued at approximately $134,000. PNC Financial Services Group Inc. boosted its position in shares of Emergent Biosolutions by 108.6% during the first quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 1,482 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Emergent Biosolutions during the first quarter valued at approximately $171,000. Financial Gravity Wealth Inc. bought a new stake in shares of Emergent Biosolutions during the first quarter valued at approximately $190,000. Finally, Sei Investments Co. boosted its position in shares of Emergent Biosolutions by 5,992.1% during the first quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 3,775 shares in the last quarter. Institutional investors own 83.00% of the company’s stock.

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald set a $62.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a research report on Tuesday, August 28th. Chardan Capital lifted their price objective on Emergent Biosolutions from $53.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, August 3rd. Argus lifted their price objective on Emergent Biosolutions to $70.00 and gave the stock an “average” rating in a research report on Tuesday, September 11th. They noted that the move was a valuation call. Cowen reiterated a “hold” rating and issued a $49.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, August 29th. Finally, Zacks Investment Research upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a research report on Tuesday, July 10th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $61.63.

About Emergent Biosolutions

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Featured Story: Dividend Aristocrat Index

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply